Skip to main content
Delhi High Court Ruling: Novo Nordisk vs Sun Pharma on Semaglutide

Litigation Update: Novo Nordisk vs Sun Pharma on Semaglutide

The Delhi High Court has passed a crucial order in the ongoing patent battle between Danish pharmaceutical giant Novo Nordisk and Indian major Sun Pharma regarding the manufacture and sale of Semaglutide.

Key Takeaways from the Order

  • Export Allowed: Sun Pharma has been permitted to manufacture and export Semaglutide to countries where Novo Nordisk does not hold a valid patent.
  • Domestic Sales Barred: The court has restrained Sun Pharma from selling the drug in the Indian market until the expiry of Novo Nordisk's specific patent in March 2026.
  • Undertaking Recorded: Justice Manmeet Pritam Singh Arora recorded Sun Pharma's undertaking that it would not commercialize the product in India during the patent term.

Background of the Dispute

Semaglutide is a GLP-1 receptor agonist used for the treatment of Type 2 Diabetes and obesity, marketed globally under brand names like Ozempic, Wegovy, and Rybelsus. Novo Nordisk alleged that Sun Pharma's proposed generic version would infringe its existing patents.

While Novo Nordisk's primary patent for the molecule expired in 2024, the company holds a secondary patent covering specific formulations and delivery mechanisms that is valid until March 2026.

Industry Impact

This ruling mirrors a similar recent order involving Dr. Reddy’s Laboratories, setting a precedent for Indian generic manufacturers. It strikes a balance by protecting the innovator's patent rights within India while allowing domestic companies to tap into global export opportunities where such patent barriers do not exist.

For more updates on pharmaceutical litigations and patent news, check out my earlier posts on e-Pharmatimes.

Comments

Post a Comment

Popular posts from this blog

Transforming Healthcare: The Role of Artificial Intelligence in Pharmaceuticals and Medical Devices.

AI in Healthcare & Pharma: How Artificial Intelligence Is Transforming Drug Discovery and Medical Devices Artificial Intelligence (AI) is reshaping the global healthcare ecosystem. From drug discovery to diagnostics and patient care, AI has become the driving force behind the next wave of innovation in the pharmaceutical and medical device sectors. This article explores how AI technologies are transforming every stage of the healthcare value chain. AI in Pharmaceutical Development Accelerating Drug Discovery AI algorithms now analyze massive biological and chemical datasets to identify potential drug candidates in record time. Machine learning models predict molecular properties, toxicity levels, and drug–target interactions — drastically reducing preclinical failure rates. Major pharma companies are partnering with AI startups to shorten drug discovery timelines by up to 50%. Optimizing Clinical Trials AI supports patient selection, risk prediction, and real-time tr...
Post a Comment
Read more

Novartis, busy with its restructuring, sells 5 eye drugs for up to $175M

The pharma monster has offered five of its ophthalmic medications to eye treatment organization Harrow for a one-time frame installment of $130 million, or more extra achievement installments of $45 million. The deal incorporates waterfall medical procedure recuperation eye drops Ilevro and Nevanac, bacterial conjunctivitis eyedrop Vigamox, irritation eye drops Maxidex and the injectable Triesence. The arrangement makes Harrow famous into "an administrative role in the U.S. ophthalmic drugs market," Imprint L. Baum, Harrow's Chief and executive, said in an assertion. "We know these items quite well and have long appreciated and respected them for the worth they have conveyed to great many U.S. eyecare experts and a huge number of their patients," Baum added. The arrangement will probably close during the main quarter of 2023. A while later, Novartis will in any case possess the items beyond the U.S. U.S. Novartis "stays focused on patients by supporting ad...
Post a Comment
Read more
Ozempic Litigation Update: Brazil Court Confirms 2026 Patent Expiry Litigation Update: Brazil Court Confirms 2026 Expiry for Ozempic Patents Posted on December 18, 2025 The global battle over GLP-1 receptor agonist patents has reached a critical milestone in South America. In a decisive move that will reshape the obesity and diabetes market, Brazilian courts have effectively confirmed that the patent exclusivity for semaglutide (the active ingredient in Ozempic, Wegovy, and Rybelsus) will end in March 2026 . For pharmaceutical investors, patients, and generic manufacturers, here is the breakdown of the recent litigation landscape in Brazil. The Core Decision: Extension Denied Novo Nordisk, the manufacturer of Ozempic, had sought to extend the validity of its Brazilian patents beyond the standard 20-year term. Their argument was...
Post a Comment
Read more